Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Chakra P Chaulagain"'
Autor:
Chakra P Chaulagain, Maria-Julia Diacovo, Amy Van, Felipe Martinez, Chieh-Lin Fu, Antonio Martin Jimenez Jimenez, Wesam Ahmed, Faiz Anwer
Publikováno v:
Clinical Medicine Insights: Blood Disorders, Vol 14 (2021)
Primary plasma cell leukemia (PCL) is a rare and aggressive variant of multiple myeloma (MM). PCL is characterized by peripheral blood involvement by malignant plasma cells and an aggressive clinical course leading to poor survival. There is consider
Externí odkaz:
https://doaj.org/article/e27556eb5a0b4a3198d71c26688f934a
Publikováno v:
Hematology Reports, Vol 16, Iss 3, Pp 559-567 (2024)
Background: Pyruvate kinase (PK) deficiency is an inherited red blood cell (RBC) enzyme disorder that results in non-immune chronic hemolytic anemia. Characteristic symptoms of PK deficiency include anemia, fatigue, splenomegaly, jaundice, gallstones
Externí odkaz:
https://doaj.org/article/b353547b2dfe415f8a3c5806e61d19ad
Autor:
Maroun Bou Zerdan, Joseph Kassab, Ludovic Saba, Elio Haroun, Morgan Bou Zerdan, Sabine Allam, Lewis Nasr, Walid Macaron, Mahinbanu Mammadli, Sarah Abou Moussa, Chakra P. Chaulagain
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous interest of research and techn
Externí odkaz:
https://doaj.org/article/88708400d0b143d18bf4f94b0a81272a
Autor:
Sabine Allam, Kristina Nasr, Farhan Khalid, Zunairah Shah, Mahammed Ziauddin Khan Suheb, Sana Mulla, Sindhu Vikash, Maroun Bou Zerdan, Faiz Anwer, Chakra P. Chaulagain
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies. Blood components then undergo molecular analysis by flow cytometry or sequencing technique
Externí odkaz:
https://doaj.org/article/0e180a79562f489e9cfc8ed0b64a1ed7
Autor:
Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, Chakra P. Chaulagain
Publikováno v:
Oncotarget. 14:384-394
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3e0cefe45a49b2149b33b8731eba934
https://doi.org/10.18632/oncotarget.28415
https://doi.org/10.18632/oncotarget.28415
Publikováno v:
Blood Research. 57:106-116
The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment has been directed to the underlying plasma cell clone with or with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c1daaafc9775a6df6ddfa7f0c8f5041
https://doi.org/10.5045/br.2022.2021227
https://doi.org/10.5045/br.2022.2021227
Autor:
Chakra P. Chaulagain
Publikováno v:
Turkish Journal of Hematology, Vol 36, Iss 4, Pp 284-285 (2019)
Externí odkaz:
https://doaj.org/article/8852911e87aa4a8da8e9715ee1bf72d3
Autor:
Prajwal Dhakal, Fiona He, Kailash Mosalpuria, Vijaya Raj Bhatt, Chakra P Chaulagain, Valerie Shostrom, Shristi Upadhyay Banskota, Nabin Khanal, Krishna Gundabolu
Publikováno v:
Leukemia & Lymphoma. 63:939-945
Clinical trials do not routinely capture long-term overall survival (OS) in acute myeloid leukemia (AML). We utilized a large National Cancer Database (NCDB) to determine different factors affecting 10-year OS in AML. For patients, 18-59 years who we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562bddb094f814727943889498b0fc83
https://doi.org/10.1080/10428194.2021.2005046
https://doi.org/10.1080/10428194.2021.2005046
Autor:
Vijaya Raj Bhatt, Krishna Gundabolu, Venkat Rajasurya, Elizabeth Lyden, Amer M. Zeidan, Prajwal Dhakal, Chakra P Chaulagain
Publikováno v:
Leuk Lymphoma
Acute promyelocytic leukemia (APL) boasts overall survival (OS) of >90% at 3 years and early mortality of 60 years. OS at 1- and 3-year were 81% and 75%, respectively. In a multivariate analysis, age ≤ 40 years, treatment at academic center, use of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655fd7f211632ab20fe2fb4230e887bb
https://doi.org/10.1080/10428194.2021.1894651
https://doi.org/10.1080/10428194.2021.1894651
Autor:
Chakra P Chaulagain, Maroun Bou Zerdan, Jack Khouri, Beth M. Faiman, Faiz Anwer, Chieh-Lin Fu, Jason Valent
Publikováno v:
Blood. 140:12530-12531
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4f03d8d3f160486b48197b774df8c00
https://doi.org/10.1182/blood-2022-157865
https://doi.org/10.1182/blood-2022-157865